One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2019-131217
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 13, 2019 |
 Citations: 20 |
Affiliation: Ark Therapeutic (United States), City of Hope, University of California, Los Angeles, Los Angeles Medical Center, Mayo Clinic, The University of Texas MD Anderson Cancer Center, University of Kansas Cancer Center, University Health Network, Princess Margaret Cancer Centre, University of Michigan–Ann Arbor, Roswell Park Cancer Institute, Cornell University, University of Alberta
Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
